S15 Ep7: Cevostamab-Based Regimens Usher In the Next Wave of Bispecific Antibody Strategies in R/R Myeloma: With Joshua Richter, MD

Welcome to OncLive On Air®!OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.In today’s episode, we had the pleasure of speaking with Joshua Richter, MD, about the rationale and implications for the phase 1 CAMMA 1 study (NCT04910568), which is investigating the bispecific antibody cevostamab (RG6160; BFCR4350A) in patients with relapsed/refractory multiple myeloma. Dr Richter is an associate professor of medicine at The Tisch Cancer Institute and director of Multiple Myeloma at the Blavatnik Family Chelsea Medical Center at Mount Sinai in New York, New York.In our exclusive interview, Dr Richter discussed the rationale for targeting FcRH5 in the development of therapies for multiple myeloma, the evaluation of cevostamab-based combination strategies in patients with relapsed/refractory disease, and what the future may hold in this research arena.